What is the role of Nitroglycerin (glyceryl trinitrate) in congestive heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Nitroglycerin is a recommended adjuvant to diuretic therapy for relief of dyspnea in patients admitted with acutely decompensated heart failure, particularly in those with hypertension, coronary ischemia, or significant mitral regurgitation, as stated in the 2013 ACCF/AHA guideline 1.

Key Points

  • Nitroglycerin acts primarily through venodilation, lowering preload and helping to rapidly reduce pulmonary congestion 1.
  • The initial recommended dose of intravenous nitroglycerin is 10-20 mcg/min, increased in increments of 5-10 mcg/min every 3-5 minutes as needed, with careful monitoring of blood pressure to avoid hypotension 2.
  • Patients should be monitored for hypotension, with systolic blood pressure ideally remaining above 90 mmHg.
  • Headaches are a common side effect that often diminishes with continued use.
  • Patients should avoid phosphodiesterase inhibitors like sildenafil while using nitroglycerin due to the risk of dangerous blood pressure drops.
  • Tolerance can develop with continuous use, so a nitrate-free period of 10-12 hours daily is recommended for long-term therapy.

Administration

  • For acute heart failure with pulmonary edema, sublingual nitroglycerin tablets (0.4 mg) can be administered every 5 minutes for up to 3 doses, or nitroglycerin spray (0.4 mg per spray) can be used with the same frequency.
  • For ongoing management, transdermal nitroglycerin patches (starting at 0.2-0.4 mg/hour and titrating up as needed) provide sustained relief.
  • Intravenous nitroglycerin is reserved for hospital settings, typically starting at 5-10 mcg/minute and titrating up by 5-10 mcg/minute every 3-5 minutes based on symptoms and blood pressure.

From the FDA Drug Label

Nitroglycerin Injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; The role of Nitroglycerin (glyceryl trinitrate) in congestive heart failure is for control of congestive heart failure in the setting of acute myocardial infarction 3.

  • The medication helps to reduce preload and afterload by dilating both arterial and venous beds, which can help to decrease left ventricular end-diastolic pressure and reduce the heart's workload.
  • This can lead to an improvement in cardiac index in patients with elevated left ventricular filling pressures and increased systemic vascular resistance. The exact mechanism by which nitroglycerin improves congestive heart failure is through the formation of free radical nitric oxide (NO), which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues, leading to vasodilatation 4.

From the Research

Role of Nitroglycerin in Congestive Heart Failure

  • Nitroglycerin is a vasodilator that can be used in the treatment of acute decompensated heart failure, particularly in patients with normotensive or hypertensive heart failure 5.
  • The choice of nitroglycerin as a treatment option depends on patient characteristics, such as the presence of ischemia, degree of congestion, and renal function 5.
  • Nitroglycerin can help reduce pulmonary wedge pressure, promote balanced arterial and venous dilation, and increase natriuresis, making it a potential treatment option for acute decompensated heart failure 6.
  • However, the use of nitroglycerin in congestive heart failure is not without limitations, and its effectiveness may vary depending on the individual patient's condition and response to treatment 7.
  • In general, the management of acute decompensated heart failure involves a comprehensive assessment of the patient's condition, identification of potential therapeutic targets, and the use of guideline-directed medical therapies, including vasodilators like nitroglycerin 7, 8.

Treatment Considerations

  • The treatment of congestive heart failure typically involves a combination of medications, including diuretics, beta-blockers, ACE inhibitors, and vasodilators like nitroglycerin 9, 8.
  • The choice of treatment depends on the patient's specific condition, including the presence of ischemia, degree of congestion, and renal function 5, 6.
  • The use of nitroglycerin in congestive heart failure should be guided by expert consensus documents and clinical trials, and further research is needed to identify novel therapeutic targets and optimize treatment strategies 7.

References

Research

Update on the Management of Acute Decompensated Heart Failure.

Current treatment options in cardiovascular medicine, 2011

Research

The treatment targets in acute decompensated heart failure.

Reviews in cardiovascular medicine, 2001

Related Questions

What is the treatment prescription for a patient in the Intensive Care Unit (ICU) with acute decompensated heart failure?
In a 72-year-old man with acute decompensated congestive heart failure who is awake, alert, using accessory respiratory muscles, has tachycardia, normotension, tachypnea, hypoxemia despite 8 L/min face mask oxygen, bilateral lower extremity edema, pulmonary edema on chest radiograph, acidemia, and hypercapnia, what is the best next step in management after initiating diuresis?
What are the medications used to treat acute decompensated heart failure?
What are the typical clinical features of acute decompensated heart failure and a simple step‑by‑step treatment plan?
In a 49-year-old woman with non‑ischemic cardiomyopathy and reduced ejection fraction presenting with acute decompensated heart failure, tachycardia, low‑normal blood pressure, elevated NT‑proBNP and volume overload, which intravenous medication is most appropriate: amiodarone, diltiazem, furosemide, or nitroprusside?
What is the blood supply for the conduit in an esophagectomy?
What is the role of Angiotensin-Converting Enzyme Inhibitors (ACEi) in secondary prevention after a Non-ST-Elevation Myocardial Infarction (NSTEMI)?
What is the half-life of carbon monoxide (CO) in the context of carbon monoxide poisoning?
Can Respiratory Syncytial Virus (RSV) cause elevated Liver Function Tests (LFTs)?
What to do for a wound site infection with surgical staples (surgical staples)?
What is the appropriate dosing for Methylene Blue (methylthioninium chloride)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.